RXRX RECURSION PHARMACEUTICALS, INC.
Price Chart
Executive Summary
Three directors at Recursion Pharmaceuticals sold a total of $271K in open-market transactions over a 7-day window. The sales represent less than 0.02% of market cap, are routine in size, and involve no C-suite executives, suggesting portfolio diversification rather than a bearish signal.
Key Financial Metrics
Actionable Insight
Monitor for any material news from the company, as these sales appear to be routine insider diversification. The small dollar amount and lack of C-suite participation suggest no imminent catalyst.
Key Facts
- Three directors (Gibson, Bumpus, Borgeson) sold shares totaling $271K
- Sales represent ~0.014% of $2.0B market cap
- No C-suite insiders participated in the cluster
- Gibson's sale was preceded by derivative conversions at $0 cost
Financial Impact
Trivial relative to market cap; no material financial impact
Risk Factors
- No significant risk identified from this insider activity
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RXRX-1780693479740 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
Insider Cluster
| $3.32 awaiting T+1 | awaiting T+1 | — | $3.32 (+0.00%) |
|
May 29, 2026
8d ago
|
Press Release
| $3.79 $3.61 | ▼ −4.75% | ▼ −4.90% | $3.32 (−12.53%) |
|
May 6, 2026
4w ago
|
Press Release
| $3.43 $3.27 | ▼ −4.66% | ▼ −4.33% | $3.32 (−3.35%) |
|
May 5, 2026
4w ago
|
Insider Cluster
| $3.37 $3.43 | ▲ +1.78% | ▲ +0.40% | $3.32 (−1.63%) |
|
Apr 7, 2026
8w ago
|
Insider Cluster
| $3.19 $3.39 | ▲ +6.27% | ▲ +3.73% | $3.32 (+3.92%) |
|
Mar 25, 2026
10w ago
|
Press Release
| $3.17 $3.15 | ▼ −0.63% | ▲ +1.14% | $3.32 (+4.57%) |
|
Mar 17, 2026
11w ago
|
Insider Cluster
| $3.42 $3.32 | ▼ −2.92% | ▼ −1.53% | $3.32 (−3.07%) |
|
Feb 25, 2026
14w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▲ +0.55% | $3.32 (−12.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access